CP7_E2alf: a safe and efficient marker vaccine strain for oral immunisation of wild boar against Classical swine fever virus (CSFV).
Wild boar are an important reservoir of Classical swine fever virus (CSFV) in several European countries, where most of the primary outbreaks in domestic pigs are directly related to the endemic disease situation in the wild boar population. Oral immunisation has been introduced as an additional control measure to accelerate CSF eradication in wild boar in Germany since 1993. Immunisation with an oral bait vaccine based on the conventionally attenuated live vaccine strain "C" proved to be safe and effective, but does not allow differentiation between infected and vaccinated animals. Therefore, we examined the vaccine efficacy of the recently constructed chimeric pestivirus CP7_E2alf, whose coding sequences for the major envelope protein E2 of BVDV strain CP7 are replaced by E2 of the CSFV strain Alfort187 [Reimann I, Depner K, Trapp S, Beer M. An avirulent chimeric pestivirus with altered cell tropism protects pigs against lethal infection with classical swine fever virus. Virology 2004;322(1):143-57]. Following oral immunisation of wild boar, CP7_E2alf proved to be completely avirulent. Furthermore, all vaccinees were fully protected from clinical disease after a highly virulent CSFV challenge infection. The immunised animals seroconverted within 3 weeks after vaccination for CSFV E2-specific and CSFV neutralising antibodies, whereas prior to challenge infection no antibodies against CSFV E(rns) were detected with an appropriate CSFV-specific marker ELISA test. Thus, the BVDV backbone of CP7_E2alf enables serological and genetic differentiation from wild type CSFV infection. In conclusion, CP7_E2alf represents the first efficient and safe marker vaccine candidate for oral immunisation of wild boar against CSFV.